Browsing Caprisa (Centre for the Aids programme of research in South Africa) by Title
Now showing items 303-322 of 448
-
Ontogeny-based immunogens for the induction of V2-directed HIV broadly neutralizing antibodies.
(John Wiley & Sons., 2017)Abstract available in pdf. -
Opportunities for treating sexually transmitted infections and reducing HIV risk in rural South Africa.
(Wiley-Blackwell., 2007)Title. Opportunities for treating sexually transmitted infections and reducing HIV risk in rural South Africa Aim. This paper is a report of a study to determine the aetiological distribution of sexually transmitted ... -
Optimal combinations of broadly neutralizing antibodies for prevention and treatment of HIV-1 clade C infection.
(Public Library of Science., 2016)Abstract available in PDF file. -
Optimizing HIV prevention for women: a review of evidence from microbicide studies and considerations for gender-sensitive microbicide introduction.
(International AIDS Society., 2015)Abstract available in pdf. -
Oral and injectable contraceptive use and HIV acquisition risk among women in four African countries : a secondary analysis of data from a microbicide trial.
(Elsevier., 2016)Abstract available in pdf. -
Organ donation, discrimination after death, anti-vaccination sentiments, and tuberculosis management.
(Springer Verlag., 2012)No abstract available. -
Overview of microbicides for the prevention of human immunodeficiency virus.
(Elsevier., 2012)Human immunodeficiency virus (HIV) prevention tools that women can use and control are urgently needed. Microbicides are chemical products applied to the vagina or rectum to prevent the sexual transmission of HIV. Four ... -
Patients’ readiness to start highly active antiretroviral treatment for HIV.
(BMJ publishing group., 2005)Assessing whether patients are ready to start antiretroviral treatment may improve HIV prevention and treatment outcomes. -
Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults.
(American Society for Microbiology., 2012)On the basis of positive preclinical data, we evaluated the safety and immunogenicity of an alphavirus replicon HIV-1 subtype C gag vaccine (AVX101), expressing a nonmyristoylated form of Gag, in two double-blind, randomized, ... -
Pilot evaluation of a second-generation electronic pill box for adherence to Bedaquiline and antiretroviral therapy in drug-resistant TB/HIV co-infected patients in KwaZulu-Natal, South Africa.
(BioMed Central., 2018)Abstract available in pdf. -
A pilot study of once-daily antiretroviral therapy integrated with Tuberculosis directly observed therapy in a resource-limited setting.
(Lippincott Williams & Wilkins., 2003)To determine the feasibility and effectiveness of integrating highly active antiretroviral therapy (HAART) into existing tuberculosis directly observed therapy (TB/DOT) programs, we performed a pilot study in an urban ... -
Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression.
(Lippincott Williams & Wilkins., 2010)Background: Both T-cell activation during early HIV-1 infection and soluble markers of immune activation during chronic infection are predictive of HIV disease progression. Although the acute phase of HIV infection is ... -
Population pharmacokinetics and pharmacodynamics of Ofloxacin in South African patients with multidrug-resistant tuberculosis.
(American Society for Microbiology., 2012)Despite the important role of fluoroquinolones and the predominant use of ofloxacin for treating multidrug-resistant tuberculosis in South Africa, there are limited data on ofloxacin pharmacokinetics in patients with ... -
Potent and broad HIV-neutralizing antibodies in memory B cells and plasma.
(American Association for the Advancement of Science., 2017)Abstract available in pdf. -
Potent and Broad Neutralization of HIV-1 Subtype C by Plasma Antibodies Targeting a Quaternary Epitope Including Residues in the V2 Loop.
(American Society for Microbiology., 2010)The targets of broadly cross-neutralizing (BCN) antibodies are of great interest in the HIV vaccine field. We have identified a subtype C HIV-1-superinfected individual, CAP256, with high-level BCN activity, and ... -
Preexposure prophylaxis for HIV prevention.
(Massachusetts Medical Society., 2012)No abstract available. -
Preferential adherence to antiretroviral therapy over tuberculosis treatment: a qualitative study of drug-resistant TB/HIV co-infected patients in South Africa.
(Taylor & Francis., 2014)Abstract available in pdf. -
Pregnancies complicated by multidrug-resistant tuberculosis and HIV co-infection in Durban, South Africa.
(International Union against Tuberculosis and Lung Disease., 2006)SETTING: Tertiary hospitals in KwaZulu Natal, South Africa. OBJECTIVE: To study the impact of multidrug-resistant tuberculosis (MDR-TB) and human immunodeficiency virus-1 (HIV-1) co-infection during pregnancy on maternal ... -
Pregnancy incidence and correlates during the HVTN 503 Phambili HIV vaccine trial conducted among South African women.
(Plos., 2011)Background: HIV prevention trials are increasingly being conducted in sub-Saharan Africa. Women at risk for HIV are also at risk of pregnancy. To maximize safety, women agree to avoid pregnancy during trials, yet pregnancies ...